All News
Filter News
Found 539 articles
-
5 Biotechs Drawing Buyout Buzz in 2018
1/24/2018
Here are five possible acquisition targets to keep an eye on. -
The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions.
-
Protagonist Therapeutics Announces Final Phase I Study Results With Novel Hepcidin Mimetic, PTG-300
12/14/2017
PTG-300 treatment was well-tolerated, with no serious adverse events or dose-limiting toxicities reported.
-
4 Possible Biotech Takeover Targets for 2018
12/12/2017
This year wasn't big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016. -
PharmaEssentia Announces Favorable Two-Year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the ASH Annual Meeting 2017
12/11/2017
Results reported last year at ASH 2016 showed that at 12 months, Ropeginterferon alfa-2b demonstrated non-inferiority to hydroxyurea in Complete Hematologic Response.
-
Incyte Release: Four-Year Phase III Data Analysis Shows Durability of Response of Jakafi (ruxolitinib) in Patients With Polycythemia Vera
12/11/2017
The pre-planned data analysis showed a durable primary response to Jakafi in patients with PV who are resistant to or intolerant of HU and the overall safety profile for Jakafi remained consistent with previously reported 80-week RESPONSE data.
-
Italfarmaco Presents Positive Phase II Study Results for Givinostat in Polycythemia Vera Patients at the ASH Annual Meeting
12/11/2017
Italfarmaco Group today announced the positive results from two clinical trials evaluating its proprietary histone deacetylase (HDAC) inhibitor givinostat in Polycythemia Vera patients.
-
Impact Biomedicines Closes First Tranche of Oberland Capital Financing Following FDA Meeting
12/1/2017
Impact Biomedicines announced that it has achieved the first milestone in the Company’s previously disclosed $90 million financing with Oberland Capital, triggering the closing on the first tranche of $20 million.
-
Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi®) for the Treatment of Essential Thrombocythemia
11/15/2017
The study is expected to enroll approximately 120 patients, 18 years or older, diagnosed with ET who are resistant to or intolerant of HU.
-
More Than 30 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 59th Annual ASH Meeting
11/2/2017
Incyte Corporation announces that more than 30 abstracts including data from its clinical development programs for Jakafi (ruxolitinib), JAK1, PI3Kδ, PIM and BRD will be presented at the upcoming ASH Annual Meeting 2017 in Atlanta, Georgia from December 9-12, 2017.
-
Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs
10/31/2017
Incyte Corporation reports 2017 third-quarter financial results, highlighting 38 percent year-on-year growth in product-related revenue, driven by increased sales of Jakafi (ruxolitinib) in the U.S. and Iclusig (ponatinib) in Europe, and royalties from ex-U.S. sales of Jakavi (ruxolitinib) by Novartis and Olumiant (baricitinib) by Lilly.
-
Startup Impact Biomedicines raises $22M to bring Fedratinib to Myelofibrosis Patients.
-
Galena Biopharma And BioVascular, Inc. Reaffirm GALE-401 Partnership
9/11/2017
-
Incyte Supports the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month
9/1/2017
-
Why Gilead Might Not Make an Oncology Buy After All
8/16/2017
-
CTI BioPharma Announces EMA Validation Of Pacritinib Marketing Authorization Application For Patients With Myelofibrosis Who Have Thrombocytopenia
7/14/2017
-
AOP Orphan Pharmaceuticals AG And PharmaEssentiaAnnounce Latest Clinical Results For Ropeginterferon Alfa-2b In Polycythemia Vera From 3 Abstracts Presented At The 22nd Congress Of The European Hematology Association In Madrid
6/26/2017
-
Boston Scientific Release: New Data From PLATINUM Diversity Study Presented At SCAI 2017 Provide Important Insights Beyond Traditional Clinically-Reported Endpoints
5/15/2017
-
Why These 3 Drugmakers Could Buy Incyte
4/13/2017
-
Incyte Raises Awareness For Myeloproliferative Neoplasms As Part Of Rare Disease Day 2017
2/28/2017